Opaleye Management Inc. Buys New Shares in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Opaleye Management Inc. bought a new stake in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Rating) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 167,500 shares of the company’s stock, valued at approximately $3,373,000. Zentalis Pharmaceuticals comprises about 1.2% of Opaleye Management Inc.’s investment portfolio, making the stock its 25th largest holding. Opaleye Management Inc. owned about 0.29% of Zentalis Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Arizona State Retirement System grew its holdings in shares of Zentalis Pharmaceuticals by 3.9% in the fourth quarter. Arizona State Retirement System now owns 12,863 shares of the company’s stock worth $259,000 after purchasing an additional 480 shares during the last quarter. Metropolitan Life Insurance Co NY grew its position in shares of Zentalis Pharmaceuticals by 24.1% in the 3rd quarter. Metropolitan Life Insurance Co NY now owns 2,828 shares of the company’s stock worth $61,000 after buying an additional 550 shares during the last quarter. Captrust Financial Advisors increased its stake in shares of Zentalis Pharmaceuticals by 15,160.0% during the first quarter. Captrust Financial Advisors now owns 763 shares of the company’s stock valued at $35,000 after buying an additional 758 shares during the period. ProShare Advisors LLC raised its holdings in shares of Zentalis Pharmaceuticals by 7.9% during the fourth quarter. ProShare Advisors LLC now owns 10,759 shares of the company’s stock valued at $217,000 after acquiring an additional 791 shares in the last quarter. Finally, AXA S.A. lifted its stake in Zentalis Pharmaceuticals by 0.4% in the third quarter. AXA S.A. now owns 228,827 shares of the company’s stock worth $4,956,000 after acquiring an additional 985 shares during the period.

Zentalis Pharmaceuticals Price Performance

Shares of ZNTL stock traded up $1.88 during trading hours on Friday, reaching $29.04. 3,581,225 shares of the company traded hands, compared to its average volume of 677,262. Zentalis Pharmaceuticals, Inc. has a 12-month low of $15.55 and a 12-month high of $32.34. The company has a market cap of $1.73 billion, a P/E ratio of -6.33 and a beta of 1.84. The firm has a 50-day moving average price of $21.12 and a 200 day moving average price of $20.81.

Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Rating) last released its quarterly earnings data on Wednesday, May 10th. The company reported ($1.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.96) by ($0.11). Sell-side analysts predict that Zentalis Pharmaceuticals, Inc. will post -4.32 EPS for the current year.

Wall Street Analysts Forecast Growth

ZNTL has been the topic of several recent analyst reports. Stifel Nicolaus cut their price target on shares of Zentalis Pharmaceuticals from $46.00 to $45.00 in a report on Thursday, May 11th. Wedbush lifted their target price on shares of Zentalis Pharmaceuticals from $31.00 to $38.00 in a research note on Friday. Jefferies Financial Group cut their target price on shares of Zentalis Pharmaceuticals from $120.00 to $70.00 in a research note on Friday, May 19th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $55.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Thursday, March 2nd. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $46.60.

Zentalis Pharmaceuticals Company Profile

(Get Rating)

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker.